Kavinsky Clifford J, Szerlip Molly, Goldsweig Andrew M, Amin Zahid, Boudoulas Konstantinos Dean, Carroll John D, Coylewright Megan, Elmariah Sammy, MacDonald Lee A, Shah Atman P, Spies Christian, Tobis Jonathan M, Messé Steven R, Senerth Emily, Falck-Ytter Yngve, Babatunde Ifeoluwa, Morgan Rebecca L
Rush University Medical Center, Chicago, Illinois.
Baylor Scott & White The Heart Hospital, Plano, Texas.
J Soc Cardiovasc Angiogr Interv. 2022 May 19;1(4):100039. doi: 10.1016/j.jscai.2022.100039. eCollection 2022 Jul-Aug.
Patent foramen ovale (PFO) is a vestigial congenital cardiovascular structure present in around 25% of adults. In most cases, PFO is entirely benign and requires no treatment. However, it may cause serious complications under certain circumstances.
These evidence-based guidelines from the Society for Cardiovascular Angiography and Interventions (SCAI) aim to support patients, clinicians, and other stakeholders in decisions about management of PFO.
SCAI convened a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The Evidence Foundation, a registered 501(c)(3) nonprofit organization, provided methodological support for the guideline-development process. Following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, the guideline panel formulated and prioritized clinical questions in population, intervention, comparison, outcome (PICO) format. A separate technical review team of clinical and methodological experts conducted systematic reviews of the evidence, synthesized data, and graded the certainty of the evidence across outcomes. The guideline panel then reconvened to formulate recommendations and supporting remarks informed by the results of the technical review and additional contextual factors described in the GRADE evidence-to-decision framework.
The panel agreed on 13 recommendations to address variations on 5 clinical scenarios.
Key recommendations address patient selection for PFO closure in the prevention of recurrent PFO-associated stroke, including populations not commonly included in randomized studies, and scenarios where the PFO closure might serve a role in the prevention of other outcomes such as migraine headaches and decompression illness. The panel has also identified future research priorities to advance the field.
卵圆孔未闭(PFO)是一种残留的先天性心血管结构,约25%的成年人中存在该结构。在大多数情况下,PFO完全是良性的,无需治疗。然而,在某些情况下,它可能会导致严重并发症。
心血管造影和介入学会(SCAI)制定的这些循证指南旨在为患者、临床医生和其他利益相关者在PFO管理决策方面提供支持。
SCAI召集了一个多学科指南小组,以平衡各方利益,尽量减少利益冲突带来的潜在偏倚。证据基金会是一家注册的501(c)(3)非营利组织,为指南制定过程提供方法学支持。遵循推荐分级评估、制定和评价(GRADE)方法,指南小组以人群、干预措施、对照、结局(PICO)格式制定并优先考虑临床问题。一个由临床和方法学专家组成的独立技术审查团队对证据进行了系统评价,综合了数据,并对各结局证据的确定性进行了分级。然后,指南小组再次召开会议,根据技术审查结果以及GRADE证据到决策框架中描述的其他背景因素,制定建议和支持性说明。
该小组就13项建议达成一致,以解决5种临床情况的差异。
关键建议涉及在预防复发性PFO相关中风方面选择PFO封堵的患者,包括随机研究中通常未纳入的人群,以及PFO封堵可能在预防其他结局(如偏头痛和减压病)中发挥作用的情况。该小组还确定了推进该领域发展的未来研究重点。